Caris Life Sciences, Inc. (CAI)财务
NASDAQ · Healthcare · Biotechnology · 员工1,846人 · CEO David Dean Halbert
- 股价
- $34.33 -5.01%
- 市值
- $97亿
- 企业价值
- $94.7亿
- 最近财报
- Q2 '26 2026-08-05提交
- 下次财报
- 2026-11-04 EPS预期 $0.03
营收(TTM)$9.9亿+85.4% 对比去年同期最近4个季度;柱状图=各季度
营业利润率(TTM)15.5%+41.3 百分点 对比去年同期营业利润 $1.53亿
净利润(TTM)$1.05亿+137.7% 对比去年同期税后,含营业外收益
自由现金流(TTM)$1.46亿+204.2% 对比去年同期资本支出 $5490万
稀释EPS(TTM)$0.36+112.7% 对比去年同期最近4个季度之和
净现金$3.41亿+12.7% 对比去年同期现金 + 短期投资 - 债务
估值与关键数据
- 市值
- $97亿 EV $94.7亿
- 营收
- $9.9亿 过去12个月
- 营收增速
- +27% FY2026年一致预期
- 净利润率
- 10.6% 净利润 / 营收,TTM
- P/E
- 92.3× 预期 285.2×(FY2026)
- P/S
- 9.8× 股价 / 营收,TTM
- EV / EBITDA
- 54.8× TTM
- 自由现金流
- $1.46亿 过去12个月
- 净利润
- $1.05亿 过去12个月
- 营收预期
- $10.3亿 FY2026年一致预期
- 盈利
- 2026-11-04 营收预期 $2.55亿
- 股息
- – 无股息
核心要点
根据披露数据计算,每条结论都附有其依据的数字。
- 最近财报(2026-08-05):营收超预期10.8%,EPS 低于预期139.2%营收$2.64亿,预期$2.38亿(+10.8%);EPS -$0.00,预期$0.01(-139.2%)。
- 营收增长放缓:同比45.4%Q2 '26营收$2.64亿,此前四个季度的平均值为99.7%。
- 营业利润率15.5%(TTM),较去年同期+41.3 百分点营收增长85.4%,营业利润增长211.2%。
- 税前利润的45.9%被营业外亏损吞噬税前利润$1.05亿,营业利润$1.53亿(TTM)。股权投资亏损等一次性项目压低了净利润和EPS,营业利润更能反映业务本身。
- 资本支出占营收的5.6%(去年为1.5%)最近4个季度投入$5490万(同比+570.6%)。自由现金流$1.46亿,相当于净利润的139.3%。
- 股东回报$3800万 = 自由现金流的25.9%回购$3800万(去年为$2.2万),股息$0,股权激励$6510万(TTM)。
- 稀释股数一年内增加2.5%Q2 '26稀释股数2.83亿,一年前为2.76亿。
- 净现金 $3.41亿现金 + 短期投资 $7.93亿,含租赁债务 $4.52亿;一年前净现金 $3.02亿。
上一季度:Q2 '26
截至2026-06-30的季度。与去年同期及财报发布前的分析师一致预期对比。
本季度与去年同期
| Q2 '26 | 去年同期 | 变化 | |
|---|---|---|---|
| 营收 | $2.64亿 | $1.81亿 | +45.4% |
| 毛利率 | 68.1% | 62.7% | +5.4 百分点 |
| 营业利润 | $2690万 | $1800万 | +49.7% |
| 营业利润率 | 10.2% | 9.9% | +0.3 百分点 |
| 净利润 | -$63.7万 | -$7180万 | +99.1% |
| 稀释EPS | -$0.00 | -$1.87 | +99.9% |
| 经营现金流 | $6140万 | $729万 | +741.8% |
| 资本支出 | $3240万 | $139万 | +2,238.9% |
| 自由现金流 | $2890万 | $590万 | +390.3% |
| R&D | $3240万 | $2500万 | +29.2% |
| 股权激励费用 | $3810万 | $2830万 | +34.6% |
实际 vs 一致预期
2026-08-05| 实际 | 一致预期 | 对比预期 | |
|---|---|---|---|
| 营收 | $2.64亿 | $2.38亿 | +10.8% |
| EPS(一致预期口径) | -$0.00 | $0.01 | -139.2% |
来自2026-08-05发布的Q2 '26财报：营收及分析师预期口径的EPS（通常为调整后），可能与上方报表中的EPS不同。
EPS与一致预期
最近8次财报营收
收入从何而来,按业务线和地区逐季展示。
营收、营业利润与增速
季度按业务线划分的营收
堆叠,季度| 分部 | Q2 '26 | 同比 | 占比 | TTM | TTM同比 | 12个季度 |
|---|---|---|---|---|---|---|
| Pharma Research And Development Services | $1150万 | -38.0% | 100.0% | – | – |
按地区划分的营收
占总额比例| 分部 | Q2 '26 | 同比 | 占比 | TTM | TTM同比 | 12个季度 |
|---|---|---|---|---|---|---|
| United States | $2.62亿 | +46.8% | 99.2% | – | – | |
| Non-US | $214万 | -33.6% | 0.8% | – | – |
分部利润
取自每份10-Q / 10-K分部附注的各披露分部营业利润(多数数据源缺少的利润拆分)。
Q3 '25分部
| 分部 | 营收 | 同比 | 营业利润 | 同比 | 利润率 | 去年同期利润率 | TTM营业利润 |
|---|---|---|---|---|---|---|---|
| Reportable Segment | $2.17亿 | – | $3260万 | – | 15.1% | – | – |
各分部营业利润
季度各分部营业利润率
季度利润率与成本结构
每一单位营收在各层级还剩多少,成本又花在哪里。
利润率
季度成本占营收比例
季度现金流与资本配置
创造了多少现金,用在何处,又有多少回到股东手中。
经营现金流、资本支出、自由现金流
季度现金用途与经营现金流
财年最近4个季度
现金流量表- 经营现金流
- $2.01亿
- 资本支出
- -$5490万
- 股票回购
- -$3800万
- 股息
- $0
- 收购
- $0
- 债务净发行
- -$891万
- 股权激励费用
- $6510万
- 自由现金流
- $1.46亿
- 股东回报 / FCF
- 25.9%
股数与EPS
季度,稀释资产负债表
各季度末的流动性、投资和债务。
现金、投资与债务
季度末估值与回报
当前估值倍数与公司自身过去五个财年对比;分析师目标价与评级。
估值倍数与回报
TTM与过去5个财年| 当前 | 5年均值 | 当前处于5年区间的位置 | |
|---|---|---|---|
| P/E(TTM) | 92.3× | 18.1× 5年中的1年 | 18.1× – 18.1× |
| EV / EBITDA | 54.8× | 320.6× 5年中的2年 | 8.6× – 632.6× |
| EV / 营收 | 9.6× | 17.3× | 7.5× – 28.2× |
| 股价 / FCF | 66.2× | 61.3× 5年中的2年 | 8.7× – 113.9× |
| 股价 / 净资产 | 16.4× | 7.0× 5年中的2年 | 0.7× – 13.2× |
| FCF收益率 | 1.5% | -0.0% | -4.6% – 11.5% |
| 投入资本回报率 | 14.7% | -48.7% | -105.2% – 5.3% |
| 净资产收益率 | 18.8% | -8.6% | -93.2% – 18.8% |
分析师
一致目标价 $28.50 (-17.0%)
区间 $22.00 – $38.00 · 评级 Buy
强烈买入0
买入7
持有1
卖出0
强烈卖出0
展望
分析师对未来财年的一致预期,以及按当前股价意味着什么。
一致预期
| 财年 | 营收 | 增速 | EPS | 增速 | 按当前股价的P/E | 分析师(EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $10.3亿 | +26.8% | $0.12 | +106.5% | 285.2× | 8 |
| FY2027 | $12.3亿 | +19.3% | $0.35 | +191.3% | 97.9× | 8 |
| FY2028 | $14.2亿 | +15.9% | $0.51 | +46.6% | 66.8× | 7 |
| FY2029 | $16.3亿 | +14.8% | $0.60 | +16.7% | 57.2× | 2 |
| FY2030 | $18.6亿 | +13.6% | $0.73 | +20.8% | 47.4× | 4 |
财务报表
利润表、资产负债表和现金流量表的每一项,含12个季度和10个财年,以金额、占营收比例或增速展示。
全部披露项目
Caris Life Sciences, Inc.在近期10-Q / 10-K文件中标记的全部258项数据,附SEC官方标签和定义,包括附注(租赁、税务、回购、员工等)。
| 项目(SEC标签) | 最近季度 | 去年同期 | 同比 | 最近财年 | 上一财年 | 同比 |
|---|---|---|---|---|---|---|
| $1亿2026-06-07 | – | – | – | – | – | |
| Accounts Payable, Current | $8600万 | $2870万 | +199.3% | $3920万 | $2780万 | +41.1% |
| Accounts Receivable, after Allowance for Credit Loss, Current | $1.17亿 | $5090万 | +129.7% | $1.12亿 | $8820万 | +27.1% |
| Accrued Bonuses, Current | $1550万 | $1350万 | +14.4% | $3150万 | $2570万 | +22.3% |
| Accrued Liabilities, Current | $1.05亿 | $6140万 | +71.6% | $8780万 | $7750万 | +13.2% |
| Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | $2.51亿 | $2.42亿 | +3.9% | $2.41亿 | $2.29亿 | +5.4% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | $52.9万 | $66.9万 | -20.9% | $93.6万 | $21万 | +345.7% |
| Additional Paid in Capital | $31.4亿 | $31.2亿 | +0.5% | $31.4亿 | $0 | – |
| Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock | $02025-12-31 | $2500万 | -100.0% | $8540万 | $9640万 | -11.3% |
| Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | – | – | – | $900万2025-06-20 | – | – |
| Advertising Expense | $310万2025-12-31 | $30万 | +933.3% | $360万 | $120万 | +200.0% |
| Amortization of Debt Discount (Premium) | $29.8万 | $776万 | -96.2% | $1280万 | $705万 | +81.0% |
| Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 2970万 | 2790万 | +6.4% | 2650万 | 2.13亿 | -87.5% |
| APIC, Share-based Payment Arrangement, Increase for Cost Recognition | $2220万 | $2830万 | -21.5% | $7000万 | $1860万 | +275.5% |
| Assets | $12.3亿 | $9.55亿 | +28.7% | $11.3亿 | $3.44亿 | +227.5% |
| Assets, Current | $10.6亿 | $8.33亿 | +26.9% | $9.98亿 | $2.16亿 | +362.5% |
| Capital Expenditures Incurred but Not yet Paid | – | – | – | $245万 | $205万 | +19.3% |
| Cash and Cash Equivalents, at Carrying Value | $8.2亿2026-03-31 | $3120万 | +2,527.8% | $7.96亿 | $6400万 | +1,145.2% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $8亿2025-12-31 | $6800万 | +1,076.0% | $8亿 | $6800万 | +1,076.0% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations | $6.93亿 | $7.23亿 | -4.1% | $8亿 | $6800万 | +1,076.0% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | -$1.31亿 | $6.87亿 | -119.0% | $7.32亿 | $802万 | +9,026.2% |
| Common Stock, Other Shares, Outstanding | 2.34万 | 4.36万 | -46.2% | 2.34万 | 66.2万 | -96.5% |
| Common Stock, Par or Stated Value Per Share | $0.00 | $0.00 | 0.0% | $0.00 | $0.00 | 0.0% |
| Common Stock, Shares Authorized | 28亿 | 28亿 | 0.0% | 28亿 | 11.5亿 | +143.5% |
| Common Stock, Shares, Issued | 2.83亿 | 2.83亿 | 0.0% | 2.84亿 | 3670万 | +674.5% |
| Common Stock, Shares, Outstanding | 2.83亿 | 2.81亿 | +0.5% | 2.83亿 | 3650万 | +674.0% |
| Common Stock, Value, Issued | $28.3万 | $28.2万 | +0.4% | $28.3万 | $3.8万 | +644.7% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | -$100万 | -$7140万 | +98.6% | -$6740万 | -$2.82亿 | +76.1% |
| Contract with Customer, Liability | $2110万 | – | – | – | – | – |
| Contract with Customer, Liability, Current | $2050万 | $534万 | +284.2% | $2450万 | $747万 | +227.9% |
| Contract with Customer, Liability, Noncurrent | $53.9万 | – | – | – | – | – |
| Contract with Customer, Liability, Revenue Recognized | – | – | – | $540万2024-12-31 | $70万 | +671.4% |
| Conversion of Stock, Amount Converted | – | – | – | $23.9亿 | $0 | – |
| Costs and Expenses | $2.37亿 | $1.99亿 | +18.8% | $7.67亿 | $6.69亿 | +14.6% |
| Debt Instrument, Unamortized Discount | $2830万2026-03-31 | – | – | $2830万 | $2830万 | 0.0% |
| Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net | $731万 | $3060万 | -76.1% | $2560万 | $3090万 | -17.2% |
| Deferred Offering Costs | – | – | – | $450万2024-12-31 | – | – |
| Deferred Tax Asset, Interest Carryforward | $4420万2025-12-31 | $3560万 | +24.1% | $4420万 | $3560万 | +24.1% |
| Deferred Tax Assets, Goodwill and Intangible Assets | $316万2025-12-31 | $356万 | -11.0% | $316万 | $356万 | -11.0% |
| Deferred Tax Assets, Gross | $4.24亿2025-12-31 | $4.34亿 | -2.3% | $4.24亿 | $4.34亿 | -2.3% |
| Deferred Tax Assets, in Process Research and Development | $02025-12-31 | $5210万 | -100.0% | $0 | $5210万 | -100.0% |
| Deferred Tax Assets, Operating Loss Carryforwards | $3.1亿2025-12-31 | $2.91亿 | +6.6% | $3.1亿 | $2.91亿 | +6.6% |
| Deferred Tax Assets, Other | $623万2025-12-31 | $196万 | +218.4% | $623万 | $196万 | +218.4% |
| Deferred Tax Assets, Property, Plant and Equipment | $375万2025-12-31 | $480万 | -21.9% | $375万 | $480万 | -21.9% |
| Deferred Tax Assets, Tax Credit Carryforwards, Research | $284万2025-12-31 | $284万 | 0.0% | $284万 | $284万 | 0.0% |
| Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | $1400万2025-12-31 | $599万 | +134.3% | $1400万 | $599万 | +134.3% |
| Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities | $1000万2025-12-31 | $845万 | +18.3% | $1000万 | $845万 | +18.3% |
| Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts | $1830万2025-12-31 | $1690万 | +8.3% | $1830万 | $1690万 | +8.3% |
| Deferred Tax Assets, Valuation Allowance | $4.1亿2025-12-31 | $4.22亿 | -2.6% | $4.1亿 | $4.22亿 | -2.6% |
| Deferred Tax Liabilities, Derivatives | $360万2025-12-31 | $346万 | +4.1% | $360万 | $346万 | +4.1% |
| Deferred Tax Liabilities, Goodwill | $28.1万2025-12-31 | $26.2万 | +7.3% | $28.1万 | $26.2万 | +7.3% |
| Deferred Tax Liabilities, Gross | $1390万2025-12-31 | $1280万 | +9.1% | $1390万 | $1280万 | +9.1% |
| Deferred Tax Liabilities, Net | $02025-12-31 | $0 | – | $0 | $0 | – |
| Deferred Tax Liabilities, Other | $02025-12-31 | $0 | – | $0 | $0 | – |
| Defined Contribution Plan, Cost | $190万2025-12-31 | $180万 | +5.6% | $840万 | $800万 | +5.0% |
| Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent | 0.0%2025-12-31 | – | – | 100.0% | – | – |
| Depreciation, Depletion and Amortization | $650万 | $640万 | +1.6% | $2260万 | $4890万 | -53.8% |
| Derivative Liability | – | – | – | $606万2024-12-31 | – | – |
| Dividends Payable | $3.84亿2025-12-31 | $0 | – | $3.84亿 | $0 | – |
| Earnings Per Share, Basic | $0.00 | -$7.97 | +100.0% | -$3.22 | -$10.66 | +69.8% |
来源:SEC companyfacts(每份10-Q / 10-K的XBRL)。现金流量表的季度数据由10-Q标记的年初至今累计数推算。分部拆分带有维度标记,在分部章节中单独展示。
数据来源
报表、分部营收、指标和预期均根据公司文件标准化。分部利润及全部披露项目:SEC EDGAR(XBRL)。 已读取的文件: 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30
数据截至 2026-11-02